Techsomed Expands AI-Guided Platform from Liver to Kidney, Gains U.S. Approval

Jerusalem, 25 September, 2025 (TPS-IL) — Israeli medtech company Techsomed has received U.S. FDA clearance to expand its BioTraceIO360 platform to kidney procedures, in addition to its liver applications. The AI-powered software helps doctors plan, guide, and verify minimally invasive treatments, offering a less invasive alternative to surgery for kidney cancer patients.

“Extending BioTraceIO360 from liver to kidney creates a unified platform that gives physicians more precision and confidence,” said Yossi Abu, Techsomed’s CEO. The move advances Techsomed’s goal of standardizing image-guided therapy across multiple organs.